Addex Therapeutics (Switzerland) Insiders
| ADXN Stock | CHF 0.04 -0.003 -7.89% |
Addex Therapeutics employs about 2 people. The company is managed by 7 executives with a total tenure of roughly 5 years. A leadership review of Addex Therapeutics matters because management quality often shapes how effectively strategy is translated into revenue growth, margins, and cash generation. The practical question is whether leadership is creating repeatable business progress instead of simply managing the narrative around the company.
| Timothy Dyer Insider CEO CoFounder |
| Werner Henrichi Insider Consultant |
Addex |
Management Team Effectiveness
The company has return on total asset (ROA) of -15.9 % which means that it generated a loss of $15.9 on every $100 of assets employed. This places it below most industry peers. Similarly, it shows a return on equity (ROE) of -72.84 %, which indicates that equity investment in it has not been earning a positive return.Addex Therapeutics holds a 6.06% of its outstanding shares held by insiders and 1.11% owned by institutional investors. Institutional ownership in Addex Therapeutics stands at roughly 1%, compared to 6% insider ownership and a public float of approximately 93%.
Holders Distribution
Institutional investors in Addex Therapeutics typically operate with more research capacity, technology, and trading scale than retail holders, which is why their activity can materially affect price behavior. One practical risk is that institutions can own millions of shares, so concentrated selling can pressure the stock quickly once sentiment changes.
Workforce Comparison
Addex Therapeutics is rated below average for number of employees across the peer group. The total workforce of Health Care industry is presently estimated at about 626. Addex Therapeutics adds roughly 2.0 in number of employees claiming only tiny portion of equities under Health Care sector.
Benchmark Summation
Operator |
This analysis covers sixty-one data points across the selected time horizon. Addex Therapeutics Price Series Summation is a cross summation of Addex Therapeutics price series and its benchmark/peer.
Notable Stakeholders
An Addex Therapeutics stakeholder is any individual or group with an interest in the outcome of the business, which is why stakeholder analysis can reveal who may influence strategy and oversight. Addex Therapeutics' stakeholders can support or challenge the entity's direction, which is why tracking them can add context around price-sensitive developments.
| Timothy Dyer | CEO CoFounder | Profile | |
| Werner Henrichi | Consultant | Profile | |
| Mikhail Kalinichev | Head Science | Profile | |
| JeanPhilippe Rocher | Head Chemistry | Profile | |
| Roger MD | Chief Director | Profile | |
| Lnaic Teyssdou | Head Finance | Profile | |
| Robert Lutjens | Head Biology | Profile |
Management Information & Data Sources
Addex Therapeutics is a micro-cap company. Executive review focuses on insiders, senior management, and employee signals. Leadership review can help separate temporary operating noise from execution issues. CEO is Timothy Dyer with 2 employees and 7 reported executives.
This section for Addex Therapeutics is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Values may update on different source schedules. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Workforce metrics tied to Addex Therapeutics offer a useful way to test whether headcount and economic output are moving in a productive direction. The business is commonly classified in the Healthcare sector and the Biotechnology industry.
Addex Therapeutics Manpower Efficiency
Return on Addex Therapeutics Manpower
| Revenue Per Employee | 205K | |
| Revenue Per Executive | 58.6K | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 701.3K | |
| Working Capital Per Employee | 1.4M | |
| Working Capital Per Executive | 391.3K |
Additional Tools for Addex Stock Analysis
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |